Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) EPS (Weighted Average and Diluted) (2019 - 2025)

CytomX Therapeutics' EPS (Weighted Average and Diluted) history spans 7 years, with the latest figure at -$0.22 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 195.65% year-over-year to -$0.22; the TTM value through Dec 2025 reached -$0.04, down 110.26%, while the annual FY2025 figure was -$0.15, 139.47% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.22 in Q4 2025 per CTMX's latest filing, down from -$0.09 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.27 in Q1 2025 to a low of -$0.53 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.16, with a median of -$0.09 recorded in 2025.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 2200.0% in 2024 against a maximum downside of 300.0% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.53 in 2021, then soared by 75.47% to -$0.13 in 2022, then soared by 107.69% to $0.01 in 2023, then soared by 2200.0% to $0.23 in 2024, then crashed by 195.65% to -$0.22 in 2025.
  • Per Business Quant, the three most recent readings for CTMX's EPS (Weighted Average and Diluted) are -$0.22 (Q4 2025), -$0.09 (Q3 2025), and $0.27 (Q1 2025).